GSA Capital Partners’s KalVista Pharmaceuticals KALV Stock Holding History

GSA Capital Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,236	Closed	-$250K	–	1679
2022 Q3	$250K	Sell	17,236 -21,414	-55%	-$299K	0.03%	1055
2022 Q2	$380K	Buy	38,650 +15,148	+64%	+$167K	0.06%	673
2022 Q1	$346K	Buy	23,502 +12,003	+104%	+$172K	0.05%	798
2021 Q4	$152K	Buy	+11,499	New	+$183K	0.02%	1269
2021 Q1	–	Sell	-22,664	Closed	-$430K	–	1290
2020 Q4	$430K	Sell	22,664 -2,802	-11%	-$48.1K	0.07%	517
2020 Q3	$321K	Buy	+25,466	New	+$318K	0.05%	684
2020 Q2	–	Sell	-16,786	Closed	-$128K	–	867
2020 Q1	$128K	Sell	16,786 -50	-0.3%	-$675	0.03%	860
2019 Q4	$300K	Buy	16,836 +6,515	+63%	+$85K	0.03%	1029
2019 Q3	$120K	Buy	+10,321	New	+$167K	0.02%	1259
2019 Q2	–	Sell	-7,371	Closed	-$211K	–	1586
2019 Q1	$211K	Buy	+7,371	New	+$160K	0.02%	1214

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GSA Capital Partners's KALV Position: Q4 2022 in Review

GSA Capital Partners sold out of KalVista Pharmaceuticals (KALV) in Q4 2022, closing a stake of 17,236 shares — an estimated $250K sold.

GSA Capital Partners first reported a position in KALV in Q1 2019 and held it in 10 quarters. The position peaked at $430K in Q4 2020. 91 funds tracked by Wall St. Rank hold KALV as of Q4 2022.

GSA Capital Partners reported no remaining KalVista Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 17,236 KalVista Pharmaceuticals shares in Q4 2022, an estimated $250K.
GSA Capital Partners first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 10 quarters.
GSA Capital Partners's KalVista Pharmaceuticals position peaked at $430K in Q4 2020.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.